报价延迟最少15分钟:2025/07/17 18:56 EDT
盘后时段
|
||||
|
572.71 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
572.71
|
|
|
| 价值评估 |
|
盈利(现时/预测)
16.40/14.00
|
|
企业价值
35.40B
|
| 资产负债 |
|
每股账面净值
89.84
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.19B
|
|
每股收益
16.24
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/17 18:56 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease. |
